Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses under a new organizational structure. Through this change, the company aims to offer the industry more agile and focused services, deeper innovation in bioprocess solutions, and stronger support in emerging modalities.

Asahi Kasei’s bioprocess-related business units have operated under Asahi Kasei Life Science since April 1st of this year. This includes virus removal filters Planova and Microfilters BioOptimal, its contract research organization (CRO) testing services performed by ViruSure of Austria, Bionique Testing Laboratories, and the U.S.-based biologics contract development and manufacturing organization (CDMO) Bionova Scientific.

“I am thrilled to announce the start of operations at Asahi Kasei Life Science, which began on April 1,” said Ken Shinomiya, President of Asahi Kasei Life Science. “Focused on the field of life science centered on the bioprocess business, we aim to expand as part of the growing Healthcare sector business, the main growth driver of the Asahi Kasei Group. As a trusted premium partner, we are dedicated to shaping the future of the pharmaceutical industry—delivering innovative, reliable solutions that drive lasting impact and empower our clients to thrive.”